How Big Pharma’s China Trials Are Escaping Scrutiny
U.S. supply chains with connections to Xinjiang and the Chinese military are heavily regulated — just not for pharmaceuticals.
Nurses prepare for infusion and injection at a hospital in Cangxian county, Cangzhou city, north Chinas Hebei province. Credit: IC Photo via Depositphotos
U.S. sanctions on Chinese companies operating in Xinjiang or with the Chinese military have reshaped supply chains from agriculture to technology. Itâ
Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
A weekly curated reading list on China from Andrew Peaple.
A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our Subscriptions page for details.
The former Biden administration officials talk about how they tried to craft rules to keep the U.S. ahead in the AI race, and why they think the Trump team’s approach has fallen short.
In an extract from his new book, China Whisperers, Robert D. Kaplan interviews Evan Medeiros on the challenges presented by a stronger and more determined China under Xi Jinping.
Corporate Risk Intelligence for National Security, Compliance & Due Diligence
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.